Top Page
Satellos Bioscience
(TSX:MSCL)
Satellos Bioscience (MSCL) vs. S&P 500 (SPY)
Satellos Bioscience Business Overview & Revenue Model
Satellos Bioscience Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.00K | Gross Profit |
| -9.53M | -8.82M | -3.73M | -119.92K | -48.16K | -1.26M | EBIT |
| -26.24M | -15.46M | -8.43M | -4.74M | -1.55M | -2.00M | EBITDA |
| -28.52M | -15.71M | -8.09M | -4.60M | -1.61M | -2.00M | Net Income Common Stockholders |
| -28.53M | -15.89M | -11.32M | -15.51M | -1.58M | -1.99M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.92M | 39.59M | 1.92M | 4.87M | 717.53K | 399.13K | Total Assets |
| 6.20M | 44.30M | 6.20M | 12.59M | 1.13M | 1.07M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 1.09M | 0.00 | Net Debt |
| -1.92M | -22.07M | -1.92M | -4.87M | 375.78K | -399.13K | Total Liabilities |
| 2.83M | 3.62M | 2.83M | 2.10M | 1.31M | 664.81K | Stockholders Equity |
| 3.37M | 40.67M | 3.37M | 10.48M | -183.84K | 408.57K |
| Cash Flow | Free Cash Flow | ||||
| -22.61M | -14.52M | -5.79M | -5.04M | -1.66M | -1.93M | Operating Cash Flow |
| -22.60M | -14.50M | -5.78M | -5.03M | -1.66M | -1.92M | Investing Cash Flow |
| 437.00K | -17.54M | -3.00K | 1.74M | 0.00 | -771.00 | Financing Cash Flow |
| 237.00K | 51.03M | 2.77M | 7.45M | 1.98M | 1.16M |
Satellos Bioscience Technical Analysis
Satellos Bioscience Peers Comparison
Satellos Bioscience Corporate Events
Satellos Bioscience successfully closed a $40 million public offering, issuing over 63 million equity securities, to fund its Phase 2 clinical program for SAT-3247. The offering was led by Bloom Burton Securities Inc. and participated by several agents. The funds will support clinical development and general corporate needs.
Satellos Bioscience is launching an overnight marketed public offering of its common shares to fund the advancement of its Phase 2 clinical development and cover general corporate expenses. The offering, led by Bloom Burton Securities Inc., is set to close around December 20, 2024, pending regulatory approvals.
Satellos Bioscience has achieved a significant milestone by dosing the first patient with Duchenne muscular dystrophy (DMD) in their Phase 1b clinical trial of SAT-3247. This development follows the successful completion of earlier safety trials, indicating the drug’s potential as a safe and tolerable treatment option for DMD. The trial aims to enroll up to 10 participants to further assess the drug’s safety and pharmacokinetics.
Satellos Bioscience, a biotech company focused on treating muscle diseases, will participate in the Oppenheimer Movers in Rare Disease Summit in New York City. The company is advancing SAT-3247, a promising small molecule drug for Duchenne muscular dystrophy, which shows potential in restoring muscle regeneration. Satellos seeks to leverage its MyoReGenX™ platform to explore further therapeutic opportunities.
Satellos Bioscience is set to participate in a live investor webinar discussing Duchenne muscular dystrophy with key opinion leaders. The event will highlight the need for innovative treatments and Satellos’ small molecule approach targeting muscle regeneration. Attendees will have the chance to engage with experts and explore new insights into the disease.
Satellos Bioscience has appointed Stephanie Brown, a seasoned biopharma expert, to its Board of Directors, aiming to leverage her extensive experience in rare disease markets to drive company growth. Brown’s leadership in product launches and strategic roles in top pharmaceutical companies aligns with Satellos’ mission to innovate treatments for muscle diseases. This strategic move is expected to bolster Satellos’ efforts in developing groundbreaking therapies.
Satellos Bioscience has appointed Stephanie Brown to its Board of Directors, bringing her extensive experience in the biopharma industry to the company. Brown’s expertise in product commercialization and organizational growth aligns with Satellos’ mission to develop innovative treatments for muscle diseases. Her leadership is expected to drive Satellos’ growth and advancement in the biotech sector.
Satellos Bioscience has made significant strides in its clinical trials for SAT-3247, aimed at treating Duchenne muscular dystrophy, with no safety issues reported. The company has a cash balance of $23.4 million as of September 30, 2024, supporting its ongoing research efforts. These advancements are crucial as Satellos continues to progress in developing life-improving medicines for muscle degenerative diseases.
Satellos Bioscience, a Toronto-based biotech firm, is set to engage with investors at several upcoming conferences in November 2024. The company, known for its innovative treatments for muscle diseases, will be participating in events hosted by Guggenheim, Stifel, and Jefferies. These engagements are part of Satellos’ strategy to showcase their advancements and attract potential investors.